Pricing Log in Create free account
Saturday 17 October 2026 Export BVS’s income statement to Excel — free account

Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%
Market cap
$1.2B
P/E
16.4×
Fwd P/E
21.4×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.31
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 — — 1 — — — — — — —
Insider Ownership 30.38%

Capital & Financial Ratios $m

Market Cap 1,160.00
Revenue 581.85
Net Income 61.48
Free Cash Flow 94.29
Net Debt 219.00
Current Ratio 1.69 (at or above 1.5: strong)
Debt/Equity 0.90
P/E ratio 16.42
Fwd P/E 21.40
P/S ratio 1.55
P/B ratio 3.25
Past 5Y EPS Growth (18.00%) (below 0%: weak)
This Y EPS Growth 14.54%
Next Y EPS Growth 18.17% (at or above 15%: strong)
Next Y revenue growth (26.58%) (below 0%: weak)
Next 5Y EPS Growth 16.02% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.9×, against a ten-year median of 1.5×; over the ten years it ranged from 0.5× in 2021 to 2.5× in 2022.
P/S against its own 10 years 84.72%
10-year low 10-year high
P/B against its own 10 years 84.93%
10-year low 10-year high
EV/Sales against its own 10 years 80.17%
10-year low 10-year high
EV/FCF against its own 10 years 15.43%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 37 42 51 29
Receivables 123 127 128 138
Inventory 91 92 82 80
Other — — — —
268 276 273 258
2023 2024 2025 Q'26
Payables 23 24 11 20
ST’ Debt 28 27 15 19
Other 5 23 4 4
175 210 160 152

Compound Annual Growth %

10y 5y 3y
Sales — 12.08% 3.52%
Cash Flow — 0.79% 0.00%
Earnings — 6.73% 0.00%
Book Value — 9.64% (17.86%)

Revenue $m

Mar Jun Sep Dec Year
’26 132 153 — — —
’25 124 148 139 158 568
’24 129 151 139 154 573
’23 119 137 121 135 512
’22 117 140 129 126 512
’21 82 110 109 130 431
’20 79 58 86 99 321
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 9 20 — — —
’25 (19) 26 30 38 75
’24 (6) 15 10 19 39
’23 2 11 (8) 10 15
’22 (21) 3 (1) 5 (14)
’21 (18) 17 11 13 23
’20 18 8 21 25 72
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 8 19 — — —
’25 (20) 25 30 37 72
’24 (6) 15 10 19 38
’23 (1) 9 (10) 10 8
’22 (24) 1 (2) 10 (15)
’21 (19) 16 9 4 9
’20 17 7 20 24 55
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.04 0.47 — — —
’25 (0.04) 0.11 0.05 0.21 0.33
’24 (0.07) (0.37) (0.07) 0.00 (0.52)
’23 (2.24) (0.06) (0.12) (0.10) (2.49)
’22 (0.19) (0.11) (1.76) (0.52) (2.59)
’21 0.59 (0.10) (0.03) (0.01) (0.15)
’20 0.19 — 0.05 0.57 0.89
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 10.74 1.65 0.80 3.90 5.81

Analyst estimates 2026–2028

Powerpack
High — — — — — 19.94 15.57 5.54 14.38 11.25
People
People Employees — — — 680 700 1,200 1,120 970 930 930
Revenue/emp, $m 0.00 0.00 0.00 0.50 0.46 0.36 0.46 0.53 0.62 0.61
Income, $m
Income, $m Revenue 275 319 319 340 321 431 512 512 573 568
Gross margin, % 66.71 73.63 73.63 73.27 72.71 70.25 64.65 64.06 67.72 68.33
EBT (6) 6 6 10 16 9 (189) (121) (52) 26
EBT margin, % (2.06) 1.91 1.91 2.85 4.96 2.20 (36.91) (23.64) (9.13) 4.53
Net income (7) 0 (12) 6 15 10 (213) (196) (47) 27
Depreciation — 0 31 30 29 35 55 57 50 47
Per share, $
Per share, $ Revenue 4.83 65.14 65.14 5.99 5.65 9.48 8.34 8.18 8.88 8.53
Earnings (0.41) (2.49) (2.49) (0.01) 0.89 (0.15) (2.59) (2.49) (0.52) 0.34
Cash flow 0.65 0.00 9.22 0.72 1.26 0.51 (0.22) 0.24 0.60 1.12
Capex 0.00 0.00 (0.52) (0.04) (0.29) (0.30) (0.02) (0.12) (0.02) (0.04)
Free cash flow 0.65 0.00 8.70 0.68 0.97 0.21 (0.24) 0.13 0.59 1.08
Book value 0.00 0.00 0.00 2.56 2.54 11.74 6.71 3.53 2.88 3.43
Shares, m 57 5 5 57 57 45 61 63 65 67
Valuation, ×
Valuation, × P/E 21.92 21.92 21.92 21.92 21.92 32.43 0.00 0.00 0.00 21.88
P/S 0.29 0.29 0.29 0.29 0.29 1.53 0.31 0.64 1.18 0.87
P/B 0.65 0.65 0.65 0.65 0.65 1.23 0.39 1.49 3.65 2.17
EV/Sales 0.61 0.61 0.61 0.61 0.61 2.25 1.07 1.34 1.70 1.30
EV/FCF 2.89 2.89 2.89 2.89 2.89 102.14 (36.50) 86.04 25.72 10.24
Cash, $m
Cash, $m Operating cash flow 37 0 45 41 72 23 (14) 15 39 75
Capex — 0 (3) (2) (17) (14) (1) (7) (1) (3)
Free cash flow 37 0 43 38 55 9 (15) 8 38 72
Balance, $m
Balance, $m Working capital — — 83 94 89 82 (31) 93 65 112
Total debt — — 195 198 188 358 418 395 336 294
Net debt — — 152 133 102 308 388 358 294 243
Shareholders’ equity — — — 146 144 534 412 221 186 228
Returns, %
Returns, % ROA 0.00 (8.12) 0.00 2.90 3.39 2.25 (12.21) (14.31) (4.70) 3.22
ROIC — 0.00 10.49 6.99 5.40 0.89 (13.06) (8.82) (1.98) 7.16
ROE 0.00 0.00 (12.49) 4.71 11.33 5.72 (33.55) (49.34) (17.76) 10.98
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Bioventus Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BVS Bioventus Inc. $1.2B 16.4× 21.4× +3.76% (above 0%: growing) +345.45% (above 0%: growing) −25.11% (below 0%: shrinking) 68.97% 12.48%
TNDM Tandem Diabetes Care, Inc. $1.2B — (loss-making) — (loss-making) +5.77% (above 0%: growing) n/m −146.34% (below 0%: shrinking) 56.87% (5.42%) Compare
IRMD iRadimed Corporation $1.1B 48.5× 48.7× +0.28% (above 0%: growing) −8.89% (below 0%: shrinking) +11.66% (above 0%: growing) 74.07% 31.23% Compare
ENOV Enovis Corporation $1.1B — (loss-making) 195× +3.23% (above 0%: growing) n/m +815.79% (above 0%: growing) 61.64% 2.99% Compare
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
Median of peers $1.1B — 48.7× +6.80% — −6.38% 62.84% (1.21%)

All 149 Medical Devices stocks →

Bioventus Inc. (BVS) key facts

  • Concern: Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.
  • Bioventus Inc. (BVS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BVS traded at $13.30, a market capitalization of $1.2 billion.
  • Return on equity was 11.0% and debt-to-equity 0.90.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 1.26 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Bioventus Inc. (BVS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BVS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com